HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 386 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.45 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,533,192 | +1.0% | 249,560 | -4.6% | 0.06% | +6.9% |
| Q2 2023 | $9,440,240 | -9.0% | 261,720 | -3.6% | 0.06% | -14.7% |
| Q1 2023 | $10,370,647 | -33.0% | 271,554 | -0.2% | 0.07% | -37.0% |
| Q4 2022 | $15,488,180 | +39.7% | 272,200 | -2.9% | 0.11% | +33.3% |
| Q3 2022 | $11,087,000 | -13.1% | 280,410 | -3.3% | 0.08% | -5.8% |
| Q2 2022 | $12,760,000 | +4.6% | 289,997 | -5.2% | 0.09% | +28.4% |
| Q1 2022 | $12,194,000 | -2.2% | 305,769 | -1.4% | 0.07% | +8.1% |
| Q4 2021 | $12,471,000 | -4.4% | 310,158 | -3.3% | 0.06% | -11.4% |
| Q3 2021 | $13,046,000 | -8.8% | 320,686 | +1.8% | 0.07% | +45.8% |
| Q2 2021 | $14,307,000 | +9.7% | 315,064 | +0.8% | 0.05% | +4.3% |
| Q1 2021 | $13,036,000 | -2.2% | 312,678 | +0.2% | 0.05% | -6.1% |
| Q4 2020 | $13,327,000 | +524.5% | 312,024 | +284.2% | 0.05% | +390.0% |
| Q3 2020 | $2,134,000 | -4.2% | 81,216 | -2.2% | 0.01% | -9.1% |
| Q2 2020 | $2,227,000 | +55.5% | 83,062 | +4.3% | 0.01% | +37.5% |
| Q1 2020 | $1,432,000 | -9.9% | 79,612 | -11.2% | 0.01% | +33.3% |
| Q4 2019 | $1,589,000 | +13.3% | 89,637 | -0.8% | 0.01% | 0.0% |
| Q3 2019 | $1,402,000 | -10.4% | 90,392 | -0.7% | 0.01% | 0.0% |
| Q2 2019 | $1,564,000 | +22.1% | 91,022 | +14.4% | 0.01% | +20.0% |
| Q1 2019 | $1,281,000 | +6.6% | 79,570 | -3.1% | 0.01% | 0.0% |
| Q4 2018 | $1,202,000 | -20.1% | 82,149 | -0.8% | 0.01% | 0.0% |
| Q3 2018 | $1,504,000 | +9.7% | 82,781 | +1.8% | 0.01% | 0.0% |
| Q2 2018 | $1,371,000 | -8.2% | 81,289 | +6.6% | 0.01% | 0.0% |
| Q1 2018 | $1,494,000 | -8.3% | 76,288 | -5.1% | 0.01% | 0.0% |
| Q4 2017 | $1,629,000 | +18.4% | 80,389 | +1.5% | 0.01% | 0.0% |
| Q3 2017 | $1,376,000 | +58.5% | 79,210 | +17.0% | 0.01% | +66.7% |
| Q2 2017 | $868,000 | -0.2% | 67,728 | +0.9% | 0.00% | 0.0% |
| Q1 2017 | $870,000 | +40.5% | 67,109 | +7.0% | 0.00% | +50.0% |
| Q4 2016 | $619,000 | -99.9% | 62,702 | -0.3% | 0.00% | -33.3% |
| Q3 2016 | $759,397,000 | +40.2% | 62,864 | +0.2% | 0.00% | +50.0% |
| Q2 2016 | $541,688,000 | -9.4% | 62,768 | -0.6% | 0.00% | 0.0% |
| Q1 2016 | $598,000,000 | -45.7% | 63,172 | -0.7% | 0.00% | -60.0% |
| Q4 2015 | $1,102,000,000 | +128039.5% | 63,602 | -0.6% | 0.01% | +25.0% |
| Q3 2015 | $860,000 | -99.9% | 64,010 | -1.5% | 0.00% | -33.3% |
| Q2 2015 | $1,467,970,000 | +51.5% | 65,012 | -4.2% | 0.01% | +50.0% |
| Q1 2015 | $968,769,000 | +51.9% | 67,841 | +2.6% | 0.00% | +33.3% |
| Q4 2014 | $637,874,000 | +2.1% | 66,101 | -3.7% | 0.00% | 0.0% |
| Q3 2014 | $624,934,000 | -8.0% | 68,674 | -0.1% | 0.00% | 0.0% |
| Q2 2014 | $678,993,000 | -19.4% | 68,724 | +3.7% | 0.00% | -25.0% |
| Q1 2014 | $842,041,000 | -4.9% | 66,302 | +12.3% | 0.00% | 0.0% |
| Q4 2013 | $885,039,000 | +33.3% | 59,042 | -1.8% | 0.00% | 0.0% |
| Q3 2013 | $663,879,000 | +34.0% | 60,134 | -3.6% | 0.00% | +33.3% |
| Q2 2013 | $495,351,000 | – | 62,386 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |